Portfolio | EVX Ventures

OUR PORTFOLIO

OUR COMPANIES REDEFINE THE THERAPEUTICS OF TOMORROW

ALTRUBIO

AltruBio is a clinical-stage biotech company focused on developing novel antibody therapeutics based on unique insights into T cell activation, to treat immunological diseases with high unmet medical needs, such as steroid-refractory acute GvHD.

Website

CARCELL BIOPHARMA INC.

Carcell Biopharma Inc. is an EVX company that develops next generation cell and gene therapies. Based in both Singapore & Shanghai, Carcell is co-founded by industry veterans with work experience across China, Singapore and Boston. Carcell is establishing an integrated R&D and manufacturing center in Shanghai Waigaoqiao, and also has a top-notch R&D team in Singapore. Carcell's two lead platforms are around engineered red blood cells for immuno-modulation, and non-viral gene delivery using lipid nanoparticles.

Website

CARMINE THERAPEUTICS

Carmine Therapeutics is an EVX Ventures company pioneering a powerful new class of genetic medicines based on engineered red blood cells extracellular vesicles (RBCEVs), founded in 2019 by EVX Ventures and Professors Harvey Lodish, Minh Le and Jiahai Shi.

Website

HUMMINGBIRD BIOSCIENCE

Hummingbird Bioscience focuses on the discovery and early development of oncology drugs, from pre-clinical target validation to proof-of-concept (Phase II Clinical Trials).

Website

JOTBODY

Jotbody is on the cutting edge of single domain antibody (sdAb, also called nanobody) discovery, production and applications. Jotbody is dedicated to offering sdAb discovery services and sdAb-based research reagents of outstanding quality to the global scientific community.

Website

LERNA BIOPHARMA

Lerna Biopharma is a preclinical stage biopharmaceutical company developing RNA therapeutics for patients with liver diseases.

Website

NUEVOCOR

Headquartered in Singapore, Nuevocor focuses on developing AAV gene therapy vectors bearing therapeutic cargo for the treatment of genetically defined cardiac diseases with high unmet need. Leveraging its novel target discovery platform, and a genetic modifier approach to gene therapy, Nuevocor aims to meaningfully improve the quality of life for patients with presently incurable genetic heart disease.

Website

PAIRX BIO

PairX Bio Pte Ltd is developing next generation cancer immunotherapies targeting shared tumor-associated antigens derived from aberrantly spliced proteins. The foundational technology was developed at Duke-NUS Medical School in Prof. David Epstein’s lab.